Basic Information
| LncRNA/CircRNA Name | FALEC |
| Synonyms | NA |
| Region | GRCh38_1:150515757-150518032 |
| Ensemble | ENSG00000228126 |
| Refseq | NR_051960 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | cervical cancer |
| ICD-0-3 | C53 |
| Methods | qPCR |
| Sample | human cervical cancer cell lines (HeLa, SiHa, C-33A, and CaSKi cells) and one human non-tumourgenic epidermal cell line (HaCaT cells), blood |
| Expression Pattern | up-regulated |
| Function Description | FALEC was significantly upregulated in the blood plasma from cervical cancer patients and had significant correlation with tumor size, the FIGO stage, and lymph node metastasis. Furthermore, FALEC overexpression could stimulate proliferation and invasion of Hela cells. FALEC was a potential molecular marker used to diagnose cervical cancer and evaluate prognosis. |
| Pubmed ID | 31248657 |
| Year | 2019 |
| Title | Up-regulation of lncRNA FALEC indicates prognosis and diagnosis values in cervical cancer |
External Links
| Links for FALEC | GenBank HGNC NONCODE |
| Links for cervical cancer | OMIM COSMIC |